摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-苯基-8-三氟甲基-喹啉-4-羧酸 | 18193-08-3

中文名称
2-苯基-8-三氟甲基-喹啉-4-羧酸
中文别名
——
英文名称
2-phenyl-8-trifluoromethyl-quinoline-4-carboxylic acid
英文别名
2-Phenyl-8-trifluormethyl-cinchoninsaeure;2-Phenyl-8-(trifluoromethyl)quinoline-4-carboxylic acid
2-苯基-8-三氟甲基-喹啉-4-羧酸化学式
CAS
18193-08-3
化学式
C17H10F3NO2
mdl
——
分子量
317.267
InChiKey
XAFQAVSXMYZKPP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    457.4±45.0 °C(Predicted)
  • 密度:
    1.390±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    23
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    50.2
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Synthesis and aldose reductase inhibitory activity of N-(quinolinyl thiocarbonyl) glycine derivatives
    摘要:
    The onset of diabetic complications may be prevented by the inhibition of aldose reductase. Derivatives of N-(quinolinyl thiocarbonyl) glycine were prepared and their in vitro and ex vivo aldose reductase inhibitory activities were tested on rat lens. The cincophen derivatives were the most potent in vitro with an enzyme inhibition value of 29% at 10(-8) M and 91% at 10(-7) M for the N-[(2-phenylquinolin-4-yl)thiocarbonyl]-N-methylglycine compound 10a This activity was shown to be dependent on the nature of the substituents and seems to be optimal for the acids; esters were found to be inactive. No compound have shown ex vivo inhibitory activity. It is concluded that the lack of ex vivo activity is likely due to a poor bioavailability or a bad penetration of the compounds in target tissue (lens).
    DOI:
    10.1016/0223-5234(92)90032-v
  • 作为产物:
    描述:
    7-三氟甲基靛红苯乙酮 在 potassium hydroxide 作用下, 以 乙醇 为溶剂, 反应 24.0h, 生成 2-苯基-8-三氟甲基-喹啉-4-羧酸
    参考文献:
    名称:
    苯喹啉瞬态受体潜在的香草酸1拮抗剂治疗疼痛:1-(2-苯基喹啉-4-羰基)-N-(4-(三氟甲基)苯基)吡咯烷-3-羧酰胺的发现
    摘要:
    本文报道的是设计,合成和药理学表征的一类在从喹古芬铅进化而来的苯基喹啉平台上构建的TRPV1拮抗剂。该设计包括三个部分:连接到脂族羧酰胺的苯基喹啉头基,该端基被束缚在苯基尾基上。该设计的优化导致鉴定出37个,其中包括一个吡咯烷连接子和一个三氟甲基-苯基尾巴。在TRPV1功能测定中,使用表达hTRPV1的细胞,有37种拮抗辣椒素诱导的Ca 2+内流,IC 50值为10.2 nM。在完整的小鼠镇痛模型中,37在不同的疼痛模型中,与阳性对照BCTC相比,它们显示出更好的抗伤害感受活性。所有这些结果表明,可以考虑将37种药物作为抗伤害性药物进一步开发的主要候选药物。
    DOI:
    10.1016/j.bmc.2017.12.048
点击查看最新优质反应信息

文献信息

  • Synthesis and analgesic-anti-inflammatory activity of certain fluorinated cinchophen analogues
    作者:Hassan Y. Aboul-Enein、Said E. Ibrahim
    DOI:10.1016/s0022-1139(00)82415-x
    日期:1992.11
    The synthesis of certain fluorinated cinchophen analogues has been achieved. All compounds show analgesic and apparent anti-inflammatory activity comparable to cinchophen and indomethacin but they are toxic at, or close, to the ‘active’ doses. The structure-activity relationship is discussed.
    已经实现了某些氟化二苯酚类似物的合成。所有化合物均显示出与cinchophen和吲哚美辛相当的镇痛和表观抗炎活性,但在“活性”剂量或接近“活性”剂量时,它们均具有毒性。讨论了结构-活性关系。
  • Pharmaceutical compositions containing naphthalene-and
    申请人:Rhone-Poulenc Sante
    公开号:US04684652A1
    公开(公告)日:1987-08-04
    Compounds of the formula: ##STR1## in which R.sub.1 is C.sub.1-6 alkyl, phenyl, C.sub.3-6 cycloalkyl, phenylalkyl, cycloalkyl-alkyl or ##STR2## R.sub.3 and R.sub.4 being H or alkyl, R.sub.5 being alkenyl or alkynyl, and the sum of the carbon atoms in R.sub.3, R.sub.4 and R.sub.5 being 2 to 5, R.sub.2 is as defined for R.sub.1 and may also represent ##STR3## in which n is 0, 1, 2 or 3, it also being possible for R.sub.1 and R.sub.2 to form, with the nitrogen atom to which they are attached, a 5-, 6- or 7-membered heterocyclic radical which can contain another hetero-atom chosen from O and N and which can carry 1 or 2 substituents, Z is phenyl, pyridinyl, thienyl, thiazol-2-yl or substituted phenyl, X and R.sub.0 are H, halogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, nitro or CF.sub.3, A represents N or CH and E represents N or CH, some of which are known compounds, are therapeutically useful compounds useful in the treatment of anxiety states or of pulmonary, renal, circulatory or cardiovascular disorders.
    分子式为:##STR1## 其中R.sub.1是C.sub.1-6烷基,苯基,C.sub.3-6环烷基,苯基烷基,环烷基烷基或##STR2## R.sub.3和R.sub.4为H或烷基,R.sub.5为烯基或炔基,R.sub.3,R.sub.4和R.sub.5中碳原子的总和为2到5,R.sub.2的定义与R.sub.1相同,也可以表示为##STR3## 其中n为0,1,2或3,R.sub.1和R.sub.2还可以与它们连接的氮原子形成一个5、6或7个成员的杂环基团,该杂环基团可以含有另一个从O和N中选择的杂原子,并且可以携带1或2个取代基,Z为苯基,吡啶基,噻吩基,噻唑-2-基或取代苯基,X和R.sub.0为H,卤素,C.sub.1-3烷基,C.sub.1-3烷氧基,硝基或CF.sub.3,A代表N或CH,E代表N或CH,其中一些是已知的化合物,是治疗焦虑状态或肺部,肾脏,循环或心血管疾病的有用化合物。
  • Pharmaceutical compositions containing azanaphthalene-carboxamide
    申请人:Rhone-Poulenc Sante
    公开号:US04711890A1
    公开(公告)日:1987-12-08
    Compounds of the formula: ##STR1## in which R.sub.1 is C.sub.1-6 alkyl, phenyl, C.sub.3-6 cycloalkyl, phenylalkyl, cycloalkyl-alkyl or ##STR2## R.sub.3 and R.sub.4 being H or alkyl, R.sub.5 being alkenyl or alkynyl, and the sum of the carbon atoms in R.sub.3, R.sub.4 and R.sub.5 being 2 to 5, R.sub.2 is as defined for R.sub.1 and may also represent ##STR3## in which n is 0, 1, 2 or 3, it also being possible for R.sub.1 and R.sub.2 to form, with the nitrogen atom to which they are attached, a 5-, 6- or 7-membered heterocyclic radical which can contain another hetero-atom chosen from O and N and which can carry 1 or 2 substituents, Z is phenyl, pyridinyl, thienyl, thiazol-2-yl or substituted phenyl, X and R.sub.0 are H, halogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, nitro or CF.sub.3, A represents N or CH and E represents N or CH, some of which are known compounds, are therapeutically useful compounds useful in the treatment of anxiety states or of pulmonary, renal, circulatory or cardiovascular disorders.
    这个化合物的式子为:##STR1## 其中R.sub.1是C.sub.1-6烷基,苯基,C.sub.3-6环烷基,苯基烷基,环烷基-烷基或##STR2## R.sub.3和R.sub.4为H或烷基,R.sub.5为烯基或炔基,且R.sub.3,R.sub.4和R.sub.5中的碳原子总数为2到5,R.sub.2与R.sub.1的定义相同,也可以表示为##STR3## 其中n为0,1,2或3,R.sub.1和R.sub.2也可以与它们附着的氮原子形成一个5、6或7成员的杂环基团,该杂环基团可以含有另一个从O和N中选择的杂原子,并且可以携带1或2个取代基,Z为苯基,吡啶基,噻吩基,噻唑-2-基或取代苯基,X和R.sub.0为H,卤素,C.sub.1-3烷基,C.sub.1-3烷氧基,硝基或CF.sub.3,A代表N或CH,E代表N或CH,其中一些已知化合物,在治疗焦虑症或肺部,肾脏,循环或心血管疾病方面有用。
  • US4684652A
    申请人:——
    公开号:US4684652A
    公开(公告)日:1987-08-04
  • US4711890A
    申请人:——
    公开号:US4711890A
    公开(公告)日:1987-12-08
查看更多